WSJ -- Merck & Co. (MRK) Chief Executive Kenneth Frazier said Thursday the recent safety issue surrounding experimental heart drug vorapaxar "raises questions about the compound and has reduced expectations." Frazier was speaking on a conference call with analysts after Merck reported better-than-expected fourth-quarter results, but lowered its financial outlook for 2011 and beyond partly due to the vorapaxar setback.
